Published Technical Disclosure Archive

Synergistic IRAK4 Degrader Combinations for Enhanced MYD88-Mutant B-Cell Lymphoma Treatment

Publication ID: 24-11857535_0003_PTD
Published: October 28, 2025
Category:Synergistic Combinations

Legal Citation

pr1or.art Inc., “Synergistic IRAK4 Degrader Combinations for Enhanced MYD88-Mutant B-Cell Lymphoma Treatment,” Published Technical Disclosure No. 24-11857535_0003_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857535_0003_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,535.

Summary of the Inventive Concept

This inventive concept integrates IRAK4 degraders with distinct technologies, such as blockchain, AI, and IoT, to create a more powerful system for treating MYD88-mutant B-cell lymphomas, offering enhanced treatment efficacy and personalized care.

Background and Problem Solved

The original patent relates to methods of treating MYD88-mutant B-cell lymphomas using IRAK4 degraders. However, these methods have limitations in terms of treatment efficacy and patient data management. The present inventive concept addresses these limitations by combining IRAK4 degraders with advanced technologies to create a more comprehensive and effective treatment system.

Detailed Description of the Inventive Concept

The inventive concept involves integrating IRAK4 degraders with blockchain-based patient data management modules, machine learning algorithms for personalized dosing schedules, immunomodulatory agents selected based on genetic profiles, and wearable devices for real-time treatment monitoring. This synergistic combination enables secure and transparent data sharing, optimized treatment regimens, and enhanced patient outcomes.

Novelty and Inventive Step

The new claims introduce the novel concept of combining IRAK4 degraders with blockchain, AI, and IoT technologies, which is not obvious from the original patent. This integration provides a significant improvement in treatment efficacy and patient care, distinguishing the inventive concept from the original patent.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept could include integrating IRAK4 degraders with other emerging technologies, such as nanotechnology or gene editing, to further enhance treatment outcomes. Variations of the concept could also involve using different types of immunomodulatory agents or alternative data analytics platforms.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in the oncology market, particularly in the treatment of MYD88-mutant B-cell lymphomas. The integration of advanced technologies with IRAK4 degraders could lead to the development of more effective and personalized treatment options, addressing a significant unmet medical need.

Field of Art

Oncology, pharmaceutical biotechnology, with specific focus on targeted cancer therapies, molecular diagnostics, and personalized medicine technologies

Person of Ordinary Skill (PHOSITA) Profile

A skilled practitioner with advanced degrees in molecular biology, oncology, or pharmaceutical sciences, familiar with targeted cancer therapies, drug development, data analytics, and emerging medical technologies

Obviousness Rationale

A PHOSITA would recognize that integrating digital technologies with targeted cancer treatments represents a predictable extension of existing personalized medicine approaches. The combination of IRAK4 degraders with data management and monitoring technologies follows established trends in precision oncology. The proposed variations leverage known techniques in AI, blockchain, and IoT to enhance treatment optimization and patient monitoring.

Obvious Combinations & Variations

Source Patent Element
IRAK4 degraders for treating MYD88-mutant B-cell lymphomas
PTD Variation
Adding blockchain-based patient data management and AI-driven dosing optimization
Obviousness Reasoning
Personalized medicine techniques are well-established, and integrating data analytics with targeted therapies represents a predictable technological progression
Source Patent Element
Specific dosing regimens for IRAK4 degraders
PTD Variation
Machine learning algorithms for predicting and personalizing dosing schedules
Obviousness Reasoning
Computational approaches to treatment optimization are standard in modern pharmaceutical research, representing an obvious application of known data science techniques
Source Patent Element
Treatment of MYD88-mutant lymphomas using targeted molecular approaches
PTD Variation
Incorporating wearable sensors and real-time biomarker monitoring
Obviousness Reasoning
Remote patient monitoring and continuous data collection are well-known techniques in precision medicine, representing a logical extension of existing treatment paradigms
Source Patent Element
Immunomodulatory approaches in cancer treatment
PTD Variation
Genetic profile-based selection of immunomodulatory agents using whole-exome sequencing
Obviousness Reasoning
Personalized selection of therapeutic agents based on genetic profiling is a standard approach in modern oncology, representing an obvious combination of known diagnostic and treatment methodologies
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857535 and the disclosed technological variations, a person of ordinary skill in the art would find the proposed combinations of IRAK4 degraders with digital health technologies to be obvious extensions of existing personalized medicine approaches. The integration of blockchain, AI, and IoT technologies with targeted cancer therapies represents a predictable and logical progression of known techniques in precision oncology, thereby rendering potential patent claims obvious under 35 U.S.C. ยง 103.

Original Patent Information

Patent NumberUS 11,857,535
TitleMethods of treating mutant lymphomas
Assignee(s)Kymera Therapeutics, Inc.